Amanda Nerstad, Lung Cancer Survivor and Advocate, posted on LinkedIn:
“Thank you to Roche for sharing my story — I’m honored to be patient 2 in the ALK vaccine trial. Grateful for the progress in ALK-positive lung cancer.”
Amanda Nerstad expressed appreciation to Roche for amplifying her story as the second participant in the ALK vaccine trial. She highlighted ongoing progress in the treatment of ALK-positive lung cancer and her advocacy as a survivor.
More posts featuring Lung Cancer.